Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16790973 | 0.94 | BRD4 (0.37) | BTKMAPK8EGFRTRIM24BRD4 | |
| SCHEMBL107748 | 0.90 | MAPK8 (0.45) | BTKMAPK8GRM5 | |
| SCHEMBL16766621 | 0.89 | BTK (0.37) | BTKMAPK8 | |
| Hydrochloric Acid SCHEMBL16766354 | 0.88 | BTK (0.36) | BTKMAPK8 | |
| SCHEMBL16802706 | 0.88 | BTK (0.38) | BTKMAPK8 | |
| Hydrochloric Acid SCHEMBL16765882 | 0.87 | BTK (0.37) | BTKMAPK8 | |
| SCHEMBL16791398 | 0.87 | BTK (0.37) | BTKMAPK8 | |
| SCHEMBL16766386 | 0.85 | BTK (0.41) | BTKMAPK8EGFR | |
| SCHEMBL16790980 | 0.85 | BTK (0.41) | BTKMAPK8TRIM24 | |
| SCHEMBL16798105 | 0.83 | BTK (0.36) | BTKMAPK8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260415-B2 | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality | GENENTECH, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150158846-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | GENENTECH, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2015082583-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158846-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | BTK, TYK2, LCK | BTK 1/4885MAPK8 754/4885EGFR 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.